



## HIV Prevention R&D Global Investment by Region in 2012

Public, philanthropic and commercial sector funding from countries investing in HIV prevention R&D\*



\* Information collected includes funding from those agencies, organizations and companies within countries that responded to the Working Group's annual survey, or where public information sources of funding were available.

## HIV Prevention R&D Trial Participants by Region in 2012\*



\* Approximation. Where data on total participants by country is not disaggregated by country, total figures are divided among countries where trial sites are located.

North America	
Canada	US\$45.4M
US	US\$1.12B
Latin America and the Caribbean	
Cuba	US\$0.08M
Western and Central Europe	
Belgium	US\$2.6M
Denmark	US\$1.8M
France	US\$16.0M
Germany	US\$2.4M
Ireland	US\$2.5M
Italy	US\$0.2M
Netherlands	US\$19.6M
Norway	US\$2.1M

Spain	US\$4.0M
Sweden	US\$1.6M
Switzerland	US\$3.4M
United Kingdom	US\$37.3M
Southeast Asia, East Asia and Oceania	
Australia	US\$6.0M
China	US\$7.0M (est.)
India	US\$1.8M
Japan	US\$1.7M
Russia	US\$0.1M
Taiwan	US\$0.48M
Sub-Saharan Africa	
South Africa	US\$7.5M

**KEY**

- North America
- Latin America and the Caribbean
- Western and Central Europe
- Eastern Europe
- Middle East and North Africa
- Southeast Asia, East Asia and Oceania
- Sub-Saharan Africa

\* Countries by region follow UNAIDS regions and countries available at [www.unaids.org/en/regionscountries/countries/](http://www.unaids.org/en/regionscountries/countries/)

The HIV Vaccines & Microbicides Resource Tracking Working Group, comprised of AVAC, the International AIDS Vaccine Initiative (IAVI), and the Joint United Nations Programme on HIV/AIDS (UNAIDS), uses a comprehensive methodology to track annual research and development (R&D) investment trends in biomedical HIV prevention. Information collected in previous years has been used by the Working Group and others to monitor levels of effort, analyze the significance of investment trends and assess the impact of public policies aimed at accelerating scientific progress towards new prevention tools against HIV.

HIV PREVENTION OPTION	TOTAL INVESTMENT 2012
Preventive Vaccines	US\$847 million
Microbicides	US\$245 million
Pre-Exposure Prophylaxis	US\$31 million
Adult Male Circumcision	US\$42 million
Treatment as Prevention	US\$98 million
<b>Total 2012*</b>	<b>US\$1.31 billion</b>

\* The Working Group defines HIV prevention R&D as including funding for: preventive HIV vaccines, microbicides, pre-exposure prophylaxis, treatment as prevention, adult male circumcision and prevention of vertical transmission. The Working Group also tracks annual investment in HSV-2 vaccine, female condom, HIV cure and therapeutic HIV vaccine R&D—these amounts are not included in the HIV prevention R&D total.